Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.